Biogen Inc.'s stock plummeted over 6.5% in pre-market trading on Wednesday as the biotech company provided a lackluster profit outlook for 2025, overshadowing better-than-expected sales of its newly launched Alzheimer's drug Leqembi.
The Cambridge, Massachusetts-based drugmaker forecast adjusted earnings per share for 2025 to range between $15.25 and $16.25, falling short of analysts' average estimate of $16.34. Biogen cited the impact of a strong U.S. dollar and intensifying competition for its core multiple sclerosis drugs as key headwinds.
Despite the disappointing guidance, Biogen reported some encouraging signs in its fourth-quarter earnings report. Sales of Leqembi, which it co-developed with Japan's Eisai Co., Ltd., reached $87 million for the quarter, surpassing analysts' expectations of $67 million. The company also announced a collaboration with Royalty Pharma to provide up to $250 million in research and development funding for its potential lupus treatment litifilimab.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.